Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

David L. Bartlett

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3099-2613; OpenAlex author ID A5051030840, A5103389364. Sources: ClinicalTrials.gov.

Their work

Papers
21
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers, 1 trial · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 2 papers · 2021: 5 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 6 papers

Papers 21

  1. Liquid biopsy for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-026-04625-x↗
  2. Author Correction: Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Co-author DOI 10.1038/s41591-026-04775-y↗
  3. Octogenarians Undergoing Pancreaticoduodenectomy versus Definitive Radiotherapy for Locoregional Therapy of Pancreatic Ductal Adenocarcinoma: A Nationwide Anal… Co-author DOI 10.1245/s10434-026-19109-y↗
  4. ASO Visual Abstract: Octogenarians Undergoing Pancreaticoduodenectomy Versus Definitive Radiotherapy for Locoregional Therapy of Pancreatic Ductal Adenocarcino… Co-author DOI 10.1245/s10434-026-19290-0↗
  5. Adjuvant Radiotherapy After Pancreaticoduodenectomy for Margin-Negative, Node-Positive Pancreatic Ductal Adenocarcinoma: A Nationwide Analysis. Co-author DOI 10.1245/s10434-026-19566-5↗
  6. ASO Visual Abstract: Adjuvant Radiotherapy After Pancreaticoduodenectomy for Margin-Negative, Node-Positive Pancreatic Ductal Adenocarcinoma: A Nationwide Anal… Co-author DOI 10.1245/s10434-026-19655-5↗
  7. Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.26510↗
  8. Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. Co-author DOI 10.1245/s10434-020-09391-9↗
  9. Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy. Co-author DOI 10.1245/s10434-020-09446-x↗
  10. A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. Co-author DOI 10.1245/s10434-021-09594-8↗
  11. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10175-y↗
  12. Long-term oncologic outcomes of robotic and open pancreatectomy in a national cohort of pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.25958↗
  13. A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Co-author DOI 10.1158/1078-0432.ccr-19-4042↗
  14. Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Co-author DOI 10.1038/cr.2017.51↗
  15. Deviations from Expected Treatment of Pancreatic Cancer in Octogenarians: Analysis of Patient and Surgeon Factors. Co-author DOI 10.1245/s10434-016-5456-0↗
  16. Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-015-4566-4↗
  17. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. Co-author DOI 10.1038/cddis.2014.445↗
  18. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Co-author DOI 10.1245/s10434-014-3842-z↗
  19. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pan… Co-author DOI 10.1245/s10434-013-3161-9↗
  20. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic adenocarcinoma following neoadjuvant therapy. Co-author DOI 10.1007/s11605-012-1839-0↗
  21. Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Co-author DOI 10.1245/s10434-010-1401-9↗

Trials 1

  1. αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies Principal investigator NCT02151448↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sricharan Chalikonda · 4 shared papers, 2026 · strength 1.38
  2. Muhammad Muntazir Mehdi Khan · 4 shared papers, 2026 · strength 1.38
  3. Casey J. Allen · 4 shared papers, 2026 · strength 1.38
  4. Amer H. Zureikat · 12 shared papers, 2012–2021 · strength 1.00
  5. Nathan Bahary · 10 shared papers, 2011–2021 · strength 0.82
  6. Herbert J. Zeh · 12 shared papers, 2011–2021 · strength 0.77
  7. Alessandro Paniccia · 5 shared papers, 2020–2021 · strength 0.56
  8. Melissa Ellen Hogg · 6 shared papers, 2014–2021 · strength 0.53
  9. John S. Bolton · 2 shared papers, 2026 · strength 0.39
  10. Caiming Xu · 2 shared papers, 2026 · strength 0.39
  11. Mitsuro Kanda · 2 shared papers, 2026 · strength 0.39
  12. Derek Cridebring · 2 shared papers, 2026 · strength 0.39
  13. Laleh Golkar Melstrom · 2 shared papers, 2026 · strength 0.39
  14. Eunsung Jun · 2 shared papers, 2026 · strength 0.39
  15. Giulia Martina Cavestro · 2 shared papers, 2026 · strength 0.39
  16. Carlos Roberto Becerra · 2 shared papers, 2026 · strength 0.39
  17. Douglas B. Evans · 2 shared papers, 2026 · strength 0.39
  18. Haiyong Han · 2 shared papers, 2026 · strength 0.39
  19. Vincent M. Chung · 2 shared papers, 2026 · strength 0.39
  20. Alessandro Mannucci · 2 shared papers, 2026 · strength 0.39
  21. Joon Oh Park · 2 shared papers, 2026 · strength 0.39
  22. Erkut Hasan Borazanci · 2 shared papers, 2026 · strength 0.39
  23. Ajay Goel · 2 shared papers, 2026 · strength 0.39
  24. Song Cheol Kim · 2 shared papers, 2026 · strength 0.39
  25. Dong Shang · 2 shared papers, 2026 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.